enforcement

FDA Publishes Five Form 483 Inspection Records

FDA posted five Form 483 inspection records involving three manufacturers, including Dr. Reddy's Laboratories in India and Qingdao Kangyuan Pharmaceutical in China, according to the agency's Office of Inspections and Investigations FOIA Electronic Reading Room.

The newly published records include a June 25, 2026, inspection of Dr. Reddy's, a drug product manufacturer, and three inspection records involving Qingdao Kangyuan, an active pharmaceutical ingredient (API) manufacturer — the Qingdao records date to 2013, 2016 and 2024.

Their availability is part of the agency’s expanded transparency initiative (see earlier story), but a significant limitation in the agency's online FOIA Electronic Reading Room makes it difficult for users to identify newly posted documents: the database does not allow records to be sorted by publication date.

Company	Inspection date	Location	FDA Form 483
Dr. Reddy's Laboratories Ltd.	June 25, 2026	India	PDF
Analytical Control Systems, Inc.	March 30, 2026	Indiana	PDF
Qingdao Kangyuan Pharmaceutical Co., Ltd.	Aug. 16, 2024	China	PDF
Qingdao Kangyuan Pharmaceutical Co., Ltd.	April 22, 2016	China	PDF
Qingdao Kangyuan Pharmaceutical Co., Ltd.	Jan. 25, 2013	China	PDF

FDA Cites Chinese Contract Research Laboratory for GLP Deficiencies

FDA investigators cited JOINN Laboratories (Suzhou) Co., a Chinese nonclinical testing laboratory, for deficiencies involving specimen tracking, laboratory procedures and animal housing facilities during a 5/11-15 inspection. The agency issued a two-observation Form 483 to the laboratory, located in Taicang, Jiangsu Province, identifying problems with compliance with

FDA OKs Imfinzi + Padcev for Bladder Cancer

FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Pfizer and Astellas Pharma’s Padcev (enfortumab vedotin-ejfv) as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy (RC), for treating adult patients with muscle invasive bladder cancer (MIBC) who are ineligible for or who

Former CDC Director Urges Swift Overton Confirmation

Former CDC Director Robert Redfield is urging the Senate to confirm Heidi Overton as FDA commissioner before the end of the year, arguing that prolonged uncertainty over the agency's leadership could undermine U.S. competitiveness in biotechnology and threaten national health security. In a recent opinion article, Redfield

The Impacts of Dose Interruptions on Cancer Drug Efficacy: FDA

Interrupting treatment with certain lung cancer drugs may have a greater adverse effect on efficacy than reducing their dosage, according to a new analysis by FDA researchers published in Clinical Cancer Research. The researchers examined patient-level data from clinical trials supporting the original FDA approvals of four epidermal growth

Read more

FDA Cites Chinese Contract Research Laboratory for GLP Deficiencies

FDA OKs Imfinzi + Padcev for Bladder Cancer

Former CDC Director Urges Swift Overton Confirmation

The Impacts of Dose Interruptions on Cancer Drug Efficacy: FDA